MA55508A - Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules - Google Patents

Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules

Info

Publication number
MA55508A
MA55508A MA055508A MA55508A MA55508A MA 55508 A MA55508 A MA 55508A MA 055508 A MA055508 A MA 055508A MA 55508 A MA55508 A MA 55508A MA 55508 A MA55508 A MA 55508A
Authority
MA
Morocco
Prior art keywords
osimertinib
treatment
lung cancer
small cell
cell lung
Prior art date
Application number
MA055508A
Other languages
English (en)
Inventor
Anthony Francis Patrick Nash
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA55508A publication Critical patent/MA55508A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055508A 2019-03-29 2020-03-27 Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules MA55508A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962825867P 2019-03-29 2019-03-29

Publications (1)

Publication Number Publication Date
MA55508A true MA55508A (fr) 2022-02-09

Family

ID=70224330

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055508A MA55508A (fr) 2019-03-29 2020-03-27 Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules

Country Status (11)

Country Link
US (1) US20220175783A1 (fr)
EP (1) EP3946346A1 (fr)
JP (1) JP2022526159A (fr)
KR (1) KR20210144844A (fr)
CN (1) CN113645976A (fr)
AU (2) AU2020250832A1 (fr)
CA (1) CA3133766A1 (fr)
EA (1) EA202192552A1 (fr)
MA (1) MA55508A (fr)
MX (1) MX2021011810A (fr)
WO (1) WO2020201097A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240050441A1 (en) * 2020-12-11 2024-02-15 Erasca, Inc. Combination therapies for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1746999T3 (pl) 2004-05-06 2012-07-31 Warner Lambert Co 4-fenyloaminochinazolin-6-yloamidy
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
WO2013014448A1 (fr) 2011-07-27 2013-01-31 Astrazeneca Ab Dérivés de 2-(anilino 2,4,5-substitué)pyrimidine utilisés comme modulateurs de l'egfr utiles pour le traitement d'un cancer
AU2014224382B2 (en) 2013-03-06 2016-11-10 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
AU2014324478A1 (en) * 2013-09-30 2016-05-05 Amgen, Inc. Nucleic acid biomarker and use thereof
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CN115590953A (zh) * 2014-05-15 2023-01-13 百时美施贵宝公司（Us） 使用抗pd-1抗体和另一种抗癌剂的组合治疗肺癌
BR112017007769B1 (pt) 2014-10-13 2023-10-10 Yuhan Corporation Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos
RU2017136709A (ru) * 2015-04-23 2019-05-23 Медиммьюн Лимитед Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr
WO2017200016A1 (fr) * 2016-05-17 2017-11-23 公益財団法人がん研究会 Agent thérapeutique pour le cancer bronchique ayant acquis une résistance à egfr-tki
WO2018156812A1 (fr) * 2017-02-22 2018-08-30 G1 Therapeutics, Inc. Traitement du cancer entraîné par egfr avec moins d'effets secondaires

Also Published As

Publication number Publication date
MX2021011810A (es) 2021-10-26
EA202192552A1 (ru) 2021-12-17
JP2022526159A (ja) 2022-05-23
CA3133766A1 (fr) 2020-10-08
AU2023233122A1 (en) 2023-10-05
AU2020250832A1 (en) 2021-11-11
KR20210144844A (ko) 2021-11-30
EP3946346A1 (fr) 2022-02-09
WO2020201097A1 (fr) 2020-10-08
CN113645976A (zh) 2021-11-12
US20220175783A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
MA51823A (fr) Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
MA45073A (fr) Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
MA51761A (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du poumon, y compris le cpnpc et d'autres cancers
MA44119A (fr) Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale
MA41805A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
MA45122A (fr) Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA44658A (fr) Procédés et kits de diagnostic et de stratification des risques de patients souffrant d'ischémie
MA42494A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA49760A (fr) Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique
MA45046A (fr) Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
MA52886A (fr) Composés de purinone et leur utilisation dans le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
EP3464638A4 (fr) Utilisation de biomarqueurs pour déterminer la sensibilité au traitement d'une maladie
DK3612517T3 (da) Bicykliske forbindelser og deres anvendelse ved behandling af cancer
MA47613A (fr) Compositions et procédés de traitement du cancer
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
DK3416957T3 (da) 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
MA47458A (fr) Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
MA47451A (fr) Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
MA47452A (fr) Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer